StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)

Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –

Arcutis Biotherapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Arcutis Biotherapeutics's gross margin for the twelve months ending Jun 30, 2026 was 91.1%. For fiscal 2025 it was 90.2%, against 90.3% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202590.2%−0.0
FY2024Dec 31, 202490.3%−1.4
FY2023Dec 31, 202391.6%+12.1
FY2022Dec 31, 202279.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202691.6%+0.8
Q1 FY2026Mar 31, 202690.7%+4.1
Q4 FY2025Dec 31, 202591.0%+0.7
Q3 FY2025Sep 30, 202591.2%+3.5
Q2 FY2025Jun 30, 202590.8%+2.0
Q1 FY2025Mar 31, 202586.6%−6.8
Q4 FY2024Dec 31, 202490.3%+6.9
Q3 FY2024Sep 30, 202487.7%−9.2
Q2 FY2024Jun 30, 202488.8%+3.7
Q1 FY2024Mar 31, 202493.4%+21.6
Q4 FY2023Dec 31, 202383.4%–
Q3 FY2023Sep 30, 202396.9%–
Q2 FY2023Jun 30, 202385.0%–
Q1 FY2023Mar 31, 202371.8%–

More Arcutis Biotherapeutics figures

See a number that looks wrong?